Contact
searchSearch
HMP Global
Login

News

Matthew Connor, MD
Conference Coverage
Evolving Strategies for the Treatment of Acute Lymphoblastic Leukemia
01/22/2026
Matthew Connor, MD
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted...
01/22/2026
Oncology
Matthew Connor, MD
Conference Coverage
IL18-Armored CAR T-Cell Therapy Produces Deep and Sustained Responses for Heavily Pretreated B-Cell Acute Lymphoblastic Leukemia
01/16/2026
Matthew Connor, MD
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported...
01/16/2026
Oncology
Alexandra Gomez Arteaga, MD
Videos
Exploring the Optimal Role of Transplant for Patients with Acute Lymphoblastic Leukemia
10/14/2025
Alexandra Gomez Arteaga, MD
Alexandra Gomez Arteaga, MD, shares insights into which patients with acute lymphoblastic leukemia should be considered for transplant, including those failing to meet MRD negativity or who have a higher genomic risk.
Alexandra Gomez Arteaga, MD, shares insights into which patients with acute lymphoblastic leukemia should be considered for transplant, including those failing to meet MRD negativity or who have a higher genomic risk.
Alexandra Gomez Arteaga, MD,...
10/14/2025
Oncology
Elias Jabbour, MD
Conference Coverage
Utilizing Immunotherapies for Optimal Treatment of Ph-Positive Acute Lymphoblastic Leukemia
06/29/2025
Elias Jabbour, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Elias Jabbour, MD, participated in a debate on the optimal regimen for treating Ph-positive ALL, highlighting the benefits of utilizing immunotherapies.
At the 2025 Great Debates in Hematologic Malignancies meeting, Elias Jabbour, MD, participated in a debate on the optimal regimen for treating Ph-positive ALL, highlighting the benefits of utilizing immunotherapies.
At the 2025 Great Debates in...
06/29/2025
Oncology
Shira Dinner, MD
Conference Coverage
Benefits of Chemotherapy Plus Allogeneic Stem Cell Transplantation as Treatment Strategy for Ph-Positive ALL
06/28/2025
Shira Dinner, MD
Shira Dinner, MD, debates the benefits of chemotherapy followed by allogeneic stem cell transplantation among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia at the 2025 Great Debates in Hematologic Malignancies.
Shira Dinner, MD, debates the benefits of chemotherapy followed by allogeneic stem cell transplantation among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia at the 2025 Great Debates in Hematologic Malignancies.
Shira Dinner, MD, debates the...
06/28/2025
Oncology
News
Autologous Hematopoietic Stem Cell Transplant Shows Safety for Late Treatment Intensification for Ph-Negative ALL
05/16/2025
Emily Estrada
Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.
Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.
Autologous hematopoietic stem...
05/16/2025
Oncology
News
Dasatinib Plus CAR T-Cell Therapy Shows Encouraging Efficacy for Patients With Newly Diagnosed Ph-Positive ALL
04/29/2025
Emily Estrada
For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.
For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.
For patients with newly...
04/29/2025
Oncology
News
Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
03/25/2025
Emily Estrada
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel...
03/25/2025
Oncology
News
Durability and Tolerability of Obecabtagene Autoleucel CAR-T Therapy for R/R B-Cell Acute Lymphoblastic Leukemia
02/07/2025
Emily Estrada
For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.
For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.
For patients with...
02/07/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use